Welcome to our dedicated page for Silo Pharma news (Ticker: SILO), a resource for investors and traders seeking the latest updates and insights on Silo Pharma stock.
Silo Pharma develops novel therapeutics and drug-delivery systems for stress-induced psychiatric disorders, chronic pain and central nervous system diseases, while also disclosing activity in cryptocurrency treasury and AI infrastructure initiatives. Company news frequently centers on SPC-15, an intranasal serotonin 5-HT4 receptor agonist program for PTSD and anxiety, as well as other pipeline work involving psychedelic-derived and traditional therapeutic approaches.
Recurring updates include patent allowances and applications in key jurisdictions, FDA and federal-policy context for psychedelic medicines, clinical-development planning, and new CNS discovery initiatives such as ibogaine-based approaches for traumatic brain injury. Corporate news also covers common-stock repurchase authorization, equity-financed asset purchases, the QwikAgents AI-agent platform, and cryptocurrency-related software assets.
Silo Pharma, Inc. (OTCQB: SILO) has partnered with Frontage Laboratories to advance its Central Nervous System Peptide, SPU-16, and Joint Homing Peptide, SPU-21, technologies toward clinical application. This agreement aims to facilitate a Pharmacokinetic Study in animals, which will analyze doses and plasma samples. CEO Eric Weisblum highlighted the potential of these peptides to enhance therapeutic effects while reducing systemic toxicity, with applications in treating central nervous system and autoimmune diseases.
Silo Pharma, a developmental stage biopharmaceutical company, announced its partnership with IBN to enhance corporate communications. This collaboration aims to leverage IBN's extensive investor distribution network to raise awareness for Silo's innovative therapeutic solutions targeting PTSD, Alzheimer’s, and other neurological disorders. Silo has established research agreements with leading universities, including studies on ketamine and psilocybin for Parkinson’s disease and inflammation. This partnership underscores Silo's commitment to advancing medical research and developing transformative treatments.
Silo Pharma (OTC QB: SILO) announced the extension of its exclusive option agreement with the University of Maryland to explore joint-homing peptides for treating rheumatoid arthritis and other autoimmune diseases. This technology aims to enhance therapeutic delivery to diseased joints, improving treatment efficacy while minimizing systemic toxicity. CEO Eric Weisblum highlighted the potential of these peptides as a revolutionary drug delivery platform, emphasizing the need for innovative therapeutics for rare diseases.
Silo Pharma, Inc. (OTCQB: SILO) announced the engagement of Donohoe Advisory Associates for consulting services related to a potential NASDAQ up-listing. This strategic move aims to enhance visibility and attract a broader investor base. CEO Eric Weisblum emphasized that listing on NASDAQ could increase liquidity for shareholders, although approval and compliance with listing requirements are not guaranteed. Silo Pharma is focused on developing psychedelic therapies for conditions like depression and PTSD, seeking transformative solutions for patients.
Silo Pharma, Inc. (OTCQB: SILO) announced the issuance of U.S. Patent No. 11,174,287 for a novel homing peptide aimed at enhancing therapeutic targeting in the central nervous system (CNS). This advancement could improve pharmacological treatments, allowing for lower dosages and reduced side effects. CEO Eric Weisblum expressed optimism about expanding their intellectual property (IP) portfolio and the potential for this technology to transform treatment options for CNS disorders. The patent emphasizes the importance of targeting neuroinflammation in CNS tissues.
Silo Pharma, Inc. (OTCQB: SILO) announced a significant milestone as its joint venture partner, Zylo Therapeutics, received its first ketamine shipment, marking the initiation of ketamine loading into the Z-Pod® transdermal technology. CEO Eric Weisblum emphasized that this advancement is pivotal for therapeutic applications of ketamine and could potentially enhance the delivery of psilocybin. Silo Pharma focuses on merging traditional therapies with psychedelic research to address mental health issues such as depression and PTSD.
Englewood Cliffs, NJ, Nov. 11, 2021 (GLOBE NEWSWIRE) -- Silo Pharma (OTCQB: SILO), a biopharmaceutical company focused on psychedelics for therapeutic use, reported its third quarter 2021 financial results and business updates. Key highlights include a research agreement with Columbia University for Alzheimer’s therapeutic development, a patent allowance from the U.S. Patent Office for CNS homing peptides, and DEA approval for a joint venture to deliver ketamine. The company has approximately $11 million in working capital and aims to uplist to the Nasdaq, enhancing long-term shareholder value.
Silo Pharma (OTCQB: SILO) has entered a sponsored research agreement with Columbia University to explore options for licensing Alzheimer’s therapeutic assets. Under the leadership of Dr. Christine Ann Denny, the initiative focuses on understanding molecular mechanisms linked to Alzheimer’s disease and memory retrieval. With 5.8 million Americans affected by Alzheimer’s, this collaboration aims to develop innovative treatments using psychedelic compounds, potentially providing significant improvements in cognitive health.
Silo Pharma (OTCQB: SILO) has entered a research agreement with Columbia University focused on developing treatments for Alzheimer’s disease. This partnership involves Dr. Christine Ann Denny, who studies the molecular mechanisms of memory and learning. Silo has the option to license certain assets related to this research, which aims to explore the therapeutic potential of ketamine for improving memory retrieval and addressing cognitive decline. The agreement represents a significant step in Silo's efforts to provide innovative solutions for patients suffering from Alzheimer’s and related conditions.
Silo Pharma (OTCQB: SILO) announced that its joint venture partner, Zylo Therapeutics, received DEA approval to develop Z-pod technology with Ketamine. CEO Eric Weisblum expressed optimism about creating a transdermal Ketamine therapeutic using this patented technology, which may also deliver Psilocybin in a controlled manner. This development aims to provide innovative solutions for patients suffering from depression, PTSD, Parkinson’s, and other neurological disorders. Updates on this partnership are anticipated as milestones are achieved.